Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Amortization of Deferred Charges (2020 - 2023)

Journey Medical (DERM) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $177000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Amortization of Deferred Charges fell 11.94% year-over-year to $177000.0, compared with a TTM value of $353000.0 through Dec 2023, down 54.16%, and an annual FY2023 reading of $353000.0, down 54.16% over the prior year.
  • Amortization of Deferred Charges was $177000.0 for Q3 2023 at Journey Medical, up from $78000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $804000.0 in Q2 2021 and bottomed at -$409000.0 in Q3 2021.
  • Average Amortization of Deferred Charges over 4 years is $175833.3, with a median of $189000.0 recorded in 2022.
  • Peak annual rise in Amortization of Deferred Charges hit 149.14% in 2022, while the deepest fall reached 73.26% in 2022.
  • Year by year, Amortization of Deferred Charges stood at $206000.0 in 2020, then fell by 19.9% to $165000.0 in 2021, then dropped by 8.48% to $151000.0 in 2022, then grew by 17.22% to $177000.0 in 2023.
  • Business Quant data shows Amortization of Deferred Charges for DERM at $177000.0 in Q3 2023, $78000.0 in Q2 2023, and $98000.0 in Q1 2023.